Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 344

1.

Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation.

Zgair A, Lee JB, Wong JCM, Taha DA, Aram J, Di Virgilio D, McArthur JW, Cheng YK, Hennig IM, Barrett DA, Fischer PM, Constantinescu CS, Gershkovich P.

Sci Rep. 2017 Nov 6;7(1):14542. doi: 10.1038/s41598-017-15026-z.

2.

Regulation of human glioblastoma cell death by combined treatment of cannabidiol, γ-radiation and small molecule inhibitors of cell signaling pathways.

Ivanov VN, Wu J, Hei TK.

Oncotarget. 2017 May 27;8(43):74068-74095. doi: 10.18632/oncotarget.18240. eCollection 2017 Sep 26.

3.

Cannabinoids Modulate Neuronal Activity and Cancer by CB1 and CB2 Receptor-Independent Mechanisms.

Soderstrom K, Soliman E, Van Dross R.

Front Pharmacol. 2017 Oct 10;8:720. doi: 10.3389/fphar.2017.00720. eCollection 2017. Review.

4.

Cannabinoids in Pain Management and Palliative Medicine.

Häuser W, Fitzcharles MA, Radbruch L, Petzke F.

Dtsch Arztebl Int. 2017 Sep 22;114(38):627-634. doi: 10.3238/arztebl.2017.0627.

5.

Nanoparticle Drones to Target Lung Cancer with Radiosensitizers and Cannabinoids.

Ngwa W, Kumar R, Moreau M, Dabney R, Herman A.

Front Oncol. 2017 Sep 19;7:208. doi: 10.3389/fonc.2017.00208. eCollection 2017.

6.

Inhibition of Wnt/β-Catenin pathway and Histone acetyltransferase activity by Rimonabant: a therapeutic target for colon cancer.

Proto MC, Fiore D, Piscopo C, Franceschelli S, Bizzarro V, Laezza C, Lauro G, Feoli A, Tosco A, Bifulco G, Sbardella G, Bifulco M, Gazzerro P.

Sci Rep. 2017 Sep 15;7(1):11678. doi: 10.1038/s41598-017-11688-x.

7.

Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies.

Fallon MT, Albert Lux E, McQuade R, Rossetti S, Sanchez R, Sun W, Wright S, Lichtman AH, Kornyeyeva E.

Br J Pain. 2017 Aug;11(3):119-133. doi: 10.1177/2049463717710042. Epub 2017 May 17.

8.
9.

Combined deficiency of the Cnr1 and Cnr2 receptors protects against age-related bone loss by osteoclast inhibition.

Sophocleous A, Marino S, Kabir D, Ralston SH, Idris AI.

Aging Cell. 2017 Oct;16(5):1051-1061. doi: 10.1111/acel.12638. Epub 2017 Jul 28.

10.

Cannabis and intractable chronic pain: an explorative retrospective analysis of Italian cohort of 614 patients.

Fanelli G, De Carolis G, Leonardi C, Longobardi A, Sarli E, Allegri M, Schatman ME.

J Pain Res. 2017 May 22;10:1217-1224. doi: 10.2147/JPR.S132814. eCollection 2017.

11.

The psychoneuroendocrine-immunotherapy of cancer: Historical evolution and clinical results.

Lissoni P, Messina G, Lissoni A, Franco R.

J Res Med Sci. 2017 Apr 26;22:45. doi: 10.4103/jrms.JRMS_255_16. eCollection 2017. Review.

12.

Systematic review of the potential role of cannabinoids as antiproliferative agents for urological cancers.

Gandhi S, Vasisth G, Kapoor A.

Can Urol Assoc J. 2017 Mar-Apr;11(3-4):E138-E142. doi: 10.5489/cuaj.4371. Epub 2017 Apr 11. Review.

13.

A Long-Term Treatment with Arachidonyl-2'-Chloroethylamide Combined with Valproate Increases Neurogenesis in a Mouse Pilocarpine Model of Epilepsy.

Andres-Mach M, Zagaja M, Haratym-Maj A, Rola R, Maj M, Haratym J, Dudra-Jastrzębska M, Łuszczki JJ.

Int J Mol Sci. 2017 Apr 25;18(5). pii: E900. doi: 10.3390/ijms18050900.

14.

Endocannabinoid system acts as a regulator of immune homeostasis in the gut.

Acharya N, Penukonda S, Shcheglova T, Hagymasi AT, Basu S, Srivastava PK.

Proc Natl Acad Sci U S A. 2017 May 9;114(19):5005-5010. doi: 10.1073/pnas.1612177114. Epub 2017 Apr 24.

15.

Cannabidiol Reduces Leukemic Cell Size - But Is It Important?

Kalenderoglou N, Macpherson T, Wright KL.

Front Pharmacol. 2017 Mar 24;8:144. doi: 10.3389/fphar.2017.00144. eCollection 2017.

16.

Endocannabinoid signalling modulates susceptibility to traumatic stress exposure.

Bluett RJ, Báldi R, Haymer A, Gaulden AD, Hartley ND, Parrish WP, Baechle J, Marcus DJ, Mardam-Bey R, Shonesy BC, Uddin MJ, Marnett LJ, Mackie K, Colbran RJ, Winder DG, Patel S.

Nat Commun. 2017 Mar 28;8:14782. doi: 10.1038/ncomms14782.

17.

Dietary ω-3 Polyunsaturated Fatty Acids Inhibit Tumor Growth in Transgenic ApcMin/+ Mice, Correlating with CB1 Receptor Up-Regulation.

Notarnicola M, Tutino V, De Nunzio V, Dituri F, Caruso MG, Giannelli G.

Int J Mol Sci. 2017 Feb 24;18(3). pii: E485. doi: 10.3390/ijms18030485.

18.

Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target.

Cassano T, Calcagnini S, Pace L, De Marco F, Romano A, Gaetani S.

Front Neurosci. 2017 Feb 2;11:30. doi: 10.3389/fnins.2017.00030. eCollection 2017. Review.

19.

Metabolic gatekeeper function of B-lymphoid transcription factors.

Chan LN, Chen Z, Braas D, Lee JW, Xiao G, Geng H, Cosgun KN, Hurtz C, Shojaee S, Cazzaniga V, Schjerven H, Ernst T, Hochhaus A, Kornblau SM, Konopleva M, Pufall MA, Cazzaniga G, Liu GJ, Milne TA, Koeffler HP, Ross TS, Sánchez-García I, Borkhardt A, Yamamoto KR, Dickins RA, Graeber TG, Müschen M.

Nature. 2017 Feb 23;542(7642):479-483. doi: 10.1038/nature21076. Epub 2017 Feb 13.

20.

Bladder cancer cell growth and motility implicate cannabinoid 2 receptor-mediated modifications of sphingolipids metabolism.

Bettiga A, Aureli M, Colciago G, Murdica V, Moschini M, Lucianò R, Canals D, Hannun Y, Hedlund P, Lavorgna G, Colombo R, Bassi R, Samarani M, Montorsi F, Salonia A, Benigni F.

Sci Rep. 2017 Feb 13;7:42157. doi: 10.1038/srep42157.

Supplemental Content

Loading ...
Support Center